PaxMedica announces receives notification to grant patent right in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2025
0mins
Should l Buy ?
Patent Approval: PaxMedica has received a Notification to Grant Patent Right for a Chinese invention patent related to treating cognitive and behavioral disorders, including autism, using a novel formulation of suramin delivered intranasally.
CEO Statement: Howard Weisman, CEO of PaxMedica, highlighted this as a significant milestone, marking the first intellectual property protection for suramin in over a century, with plans to pursue similar patents in other jurisdictions, including the United States.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
